ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 001034

Motivation, reward, and Parkinson's disease: influence of dopatherapy

Identifieur interne : 001034 ( PascalFrancis/Corpus ); précédent : 001033; suivant : 001035

Motivation, reward, and Parkinson's disease: influence of dopatherapy

Auteurs : V. Czernecki ; B. Pillon ; J. L. Houeto ; J. B. Pochon ; R. Levy ; B. Dubois

Source :

Neuropsychologia [ 0028-3932 ] ; 2002.

RBID : Pascal:03-0004494

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Motivation, Récompense, Renforcement, Chimiothérapie, Lévodopa, Dopamine, Traitement, Homme.

English descriptors

KwdEn :
- Chemotherapy, Dopamine, Human, Levodopa, Motivation, Parkinson disease, Reinforcement, Reward, Treatment.

Abstract

"Orbitofrontal" and "cingulate" striatofrontal loops and the mesolimbic dopaminergic system that modulates their function have been implicated in motivation and sensitivity to reinforcement in animals. Parkinson's disease (PD) provides a model to assess their implications in humans. The aims of the study were to investigate motivation and sensitivity to reinforcement in non-demented and -depressed PD patients and to evaluate the influence of dopaminergic therapy by comparing patients in "on" (with L-Dopa) and "off" (without L-Dopa) states. Twenty-three PD patients were compared, in both the "on" and "off" states, to 28 controls, using: (1) an Apathy Scale; (2) Stimulus-Reward Learning, Reversal, and Extinction tasks; and (3) a Gambling task. PD patients were found: (1) mildly apathetic; (2) impaired on Stimulus-Reward Learning and Reversal, but not on Extinction; and (3) able to progress in the Gambling task during the first, but not the second assessment. There was no significant correlation between these various deficits. L-Dopa treatment clearly improved motivation, but had more limited and contrasting effects on other variables, decreasing the number of omission errors in Reversal, but increasing the number of perseveration errors in Extinction. These results suggest: (1) an implication of striatofrontal loops in human motivation and explicit and implicit sensitivity to reinforcement; (2) a positive influence of L-Dopa treatment on the subjective evaluation of motivation, but contrasting effects on reward sensitivity.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0028-3932`
A02	`01`			`@0 NUPSA6`
A03		`1`		`@0 Neuropsychologia`
A05				`@2 40`
A06				`@2 13`
A08	`01`	`1`	`ENG`	`@1 Motivation, reward, and Parkinson's disease: influence of dopatherapy`
A11	`01`	`1`		`@1 CZERNECKI (V.)`
A11	`02`	`1`		`@1 PILLON (B.)`
A11	`03`	`1`		`@1 HOUETO (J. L.)`
A11	`04`	`1`		`@1 POCHON (J. B.)`
A11	`05`	`1`		`@1 LEVY (R.)`
A11	`06`	`1`		`@1 DUBOIS (B.)`
A14	`01`			`@1 INSERM E 007, Hôpital de la Salpêytière @2 Paris @3 FRA @Z 1 aut. @Z 2 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut.`
A14	`02`			`@1 Fédération de Neurologie, Hôpital de la Salpêtrière, 47 Blvd de l'Hôpital @2 75651 Paris @3 FRA @Z 2 aut. @Z 3 aut. @Z 5 aut. @Z 6 aut.`
A20				`@1 2257-2267`
A21				`@1 2002`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 11143 @5 354000106712130060`
A44				`@0 0000 @1 © 2003 INIST-CNRS. All rights reserved.`
A45				`@0 49 ref.`
A47	`01`	`1`		`@0 03-0004494`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neuropsychologia`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 "Orbitofrontal" and "cingulate" striatofrontal loops and the mesolimbic dopaminergic system that modulates their function have been implicated in motivation and sensitivity to reinforcement in animals. Parkinson's disease (PD) provides a model to assess their implications in humans. The aims of the study were to investigate motivation and sensitivity to reinforcement in non-demented and -depressed PD patients and to evaluate the influence of dopaminergic therapy by comparing patients in "on" (with L-Dopa) and "off" (without L-Dopa) states. Twenty-three PD patients were compared, in both the "on" and "off" states, to 28 controls, using: (1) an Apathy Scale; (2) Stimulus-Reward Learning, Reversal, and Extinction tasks; and (3) a Gambling task. PD patients were found: (1) mildly apathetic; (2) impaired on Stimulus-Reward Learning and Reversal, but not on Extinction; and (3) able to progress in the Gambling task during the first, but not the second assessment. There was no significant correlation between these various deficits. L-Dopa treatment clearly improved motivation, but had more limited and contrasting effects on other variables, decreasing the number of omission errors in Reversal, but increasing the number of perseveration errors in Extinction. These results suggest: (1) an implication of striatofrontal loops in human motivation and explicit and implicit sensitivity to reinforcement; (2) a positive influence of L-Dopa treatment on the subjective evaluation of motivation, but contrasting effects on reward sensitivity.
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Motivation @5 02`
C03	`02`	`X`	`ENG`	`@0 Motivation @5 02`
C03	`02`	`X`	`SPA`	`@0 Motivación @5 02`
C03	`03`	`X`	`FRE`	`@0 Récompense @5 03`
C03	`03`	`X`	`ENG`	`@0 Reward @5 03`
C03	`03`	`X`	`SPA`	`@0 Recompensa @5 03`
C03	`04`	`X`	`FRE`	`@0 Renforcement @5 04`
C03	`04`	`X`	`ENG`	`@0 Reinforcement @5 04`
C03	`04`	`X`	`SPA`	`@0 Reforzamiento @5 04`
C03	`05`	`X`	`FRE`	`@0 Chimiothérapie @5 05`
C03	`05`	`X`	`ENG`	`@0 Chemotherapy @5 05`
C03	`05`	`X`	`SPA`	`@0 Quimioterapia @5 05`
C03	`06`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 06`
C03	`06`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 06`
C03	`06`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 06`
C03	`07`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 07`
C03	`07`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 07`
C03	`07`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 07`
C03	`08`	`X`	`FRE`	`@0 Traitement @5 08`
C03	`08`	`X`	`ENG`	`@0 Treatment @5 08`
C03	`08`	`X`	`SPA`	`@0 Tratamiento @5 08`
C03	`09`	`X`	`FRE`	`@0 Homme @5 17`
C03	`09`	`X`	`ENG`	`@0 Human @5 17`
C03	`09`	`X`	`SPA`	`@0 Hombre @5 17`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Antiparkinsonien @5 42`
C07	`06`	`X`	`ENG`	`@0 Antiparkinson agent @5 42`
C07	`06`	`X`	`SPA`	`@0 Antiparkinsoniano @5 42`
N21				`@1 001`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 03-0004494 INIST
ET :	Motivation, reward, and Parkinson's disease: influence of dopatherapy
AU :	CZERNECKI (V.); PILLON (B.); HOUETO (J. L.); POCHON (J. B.); LEVY (R.); DUBOIS (B.)
AF :	INSERM E 007, Hôpital de la Salpêytière/Paris/France (1 aut., 2 aut., 4 aut., 5 aut., 6 aut.); Fédération de Neurologie, Hôpital de la Salpêtrière, 47 Blvd de l'Hôpital/75651 Paris/France (2 aut., 3 aut., 5 aut., 6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Neuropsychologia; ISSN 0028-3932; Coden NUPSA6; Royaume-Uni; Da. 2002; Vol. 40; No. 13; Pp. 2257-2267; Bibl. 49 ref.
LA :	Anglais
EA :	"Orbitofrontal" and "cingulate" striatofrontal loops and the mesolimbic dopaminergic system that modulates their function have been implicated in motivation and sensitivity to reinforcement in animals. Parkinson's disease (PD) provides a model to assess their implications in humans. The aims of the study were to investigate motivation and sensitivity to reinforcement in non-demented and -depressed PD patients and to evaluate the influence of dopaminergic therapy by comparing patients in "on" (with L-Dopa) and "off" (without L-Dopa) states. Twenty-three PD patients were compared, in both the "on" and "off" states, to 28 controls, using: (1) an Apathy Scale; (2) Stimulus-Reward Learning, Reversal, and Extinction tasks; and (3) a Gambling task. PD patients were found: (1) mildly apathetic; (2) impaired on Stimulus-Reward Learning and Reversal, but not on Extinction; and (3) able to progress in the Gambling task during the first, but not the second assessment. There was no significant correlation between these various deficits. L-Dopa treatment clearly improved motivation, but had more limited and contrasting effects on other variables, decreasing the number of omission errors in Reversal, but increasing the number of perseveration errors in Extinction. These results suggest: (1) an implication of striatofrontal loops in human motivation and explicit and implicit sensitivity to reinforcement; (2) a positive influence of L-Dopa treatment on the subjective evaluation of motivation, but contrasting effects on reward sensitivity.
CC :	002B02B06
FD :	Parkinson maladie; Motivation; Récompense; Renforcement; Chimiothérapie; Lévodopa; Dopamine; Traitement; Homme
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Antiparkinsonien
ED :	Parkinson disease; Motivation; Reward; Reinforcement; Chemotherapy; Levodopa; Dopamine; Treatment; Human
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Antiparkinson agent
SD :	Parkinson enfermedad; Motivación; Recompensa; Reforzamiento; Quimioterapia; Levodopa; Dopamina; Tratamiento; Hombre
LO :	INIST-11143.354000106712130060
ID :	03-0004494

Links to Exploration step

Pascal:03-0004494

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Motivation, reward, and Parkinson's disease: influence of dopatherapy</title>
<author><name sortKey="Czernecki, V" sort="Czernecki, V" uniqKey="Czernecki V" first="V." last="Czernecki">V. Czernecki</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM E 007, Hôpital de la Salpêytière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pillon, B" sort="Pillon, B" uniqKey="Pillon B" first="B." last="Pillon">B. Pillon</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM E 007, Hôpital de la Salpêytière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Fédération de Neurologie, Hôpital de la Salpêtrière, 47 Blvd de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Houeto, J L" sort="Houeto, J L" uniqKey="Houeto J" first="J. L." last="Houeto">J. L. Houeto</name>
<affiliation><inist:fA14 i1="02"><s1>Fédération de Neurologie, Hôpital de la Salpêtrière, 47 Blvd de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pochon, J B" sort="Pochon, J B" uniqKey="Pochon J" first="J. B." last="Pochon">J. B. Pochon</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM E 007, Hôpital de la Salpêytière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Levy, R" sort="Levy, R" uniqKey="Levy R" first="R." last="Levy">R. Levy</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM E 007, Hôpital de la Salpêytière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Fédération de Neurologie, Hôpital de la Salpêtrière, 47 Blvd de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B." last="Dubois">B. Dubois</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM E 007, Hôpital de la Salpêytière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Fédération de Neurologie, Hôpital de la Salpêtrière, 47 Blvd de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0004494</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 03-0004494 INIST</idno>
<idno type="RBID">Pascal:03-0004494</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001034</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Motivation, reward, and Parkinson's disease: influence of dopatherapy</title>
<author><name sortKey="Czernecki, V" sort="Czernecki, V" uniqKey="Czernecki V" first="V." last="Czernecki">V. Czernecki</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM E 007, Hôpital de la Salpêytière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pillon, B" sort="Pillon, B" uniqKey="Pillon B" first="B." last="Pillon">B. Pillon</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM E 007, Hôpital de la Salpêytière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Fédération de Neurologie, Hôpital de la Salpêtrière, 47 Blvd de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Houeto, J L" sort="Houeto, J L" uniqKey="Houeto J" first="J. L." last="Houeto">J. L. Houeto</name>
<affiliation><inist:fA14 i1="02"><s1>Fédération de Neurologie, Hôpital de la Salpêtrière, 47 Blvd de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pochon, J B" sort="Pochon, J B" uniqKey="Pochon J" first="J. B." last="Pochon">J. B. Pochon</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM E 007, Hôpital de la Salpêytière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Levy, R" sort="Levy, R" uniqKey="Levy R" first="R." last="Levy">R. Levy</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM E 007, Hôpital de la Salpêytière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Fédération de Neurologie, Hôpital de la Salpêtrière, 47 Blvd de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B." last="Dubois">B. Dubois</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM E 007, Hôpital de la Salpêytière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Fédération de Neurologie, Hôpital de la Salpêtrière, 47 Blvd de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neuropsychologia</title>
<title level="j" type="abbreviated">Neuropsychologia</title>
<idno type="ISSN">0028-3932</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neuropsychologia</title>
<title level="j" type="abbreviated">Neuropsychologia</title>
<idno type="ISSN">0028-3932</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chemotherapy</term>
<term>Dopamine</term>
<term>Human</term>
<term>Levodopa</term>
<term>Motivation</term>
<term>Parkinson disease</term>
<term>Reinforcement</term>
<term>Reward</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Motivation</term>
<term>Récompense</term>
<term>Renforcement</term>
<term>Chimiothérapie</term>
<term>Lévodopa</term>
<term>Dopamine</term>
<term>Traitement</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">"Orbitofrontal" and "cingulate" striatofrontal loops and the mesolimbic dopaminergic system that modulates their function have been implicated in motivation and sensitivity to reinforcement in animals. Parkinson's disease (PD) provides a model to assess their implications in humans. The aims of the study were to investigate motivation and sensitivity to reinforcement in non-demented and -depressed PD patients and to evaluate the influence of dopaminergic therapy by comparing patients in "on" (with L-Dopa) and "off" (without L-Dopa) states. Twenty-three PD patients were compared, in both the "on" and "off" states, to 28 controls, using: (1) an Apathy Scale; (2) Stimulus-Reward Learning, Reversal, and Extinction tasks; and (3) a Gambling task. PD patients were found: (1) mildly apathetic; (2) impaired on Stimulus-Reward Learning and Reversal, but not on Extinction; and (3) able to progress in the Gambling task during the first, but not the second assessment. There was no significant correlation between these various deficits. L-Dopa treatment clearly improved motivation, but had more limited and contrasting effects on other variables, decreasing the number of omission errors in Reversal, but increasing the number of perseveration errors in Extinction. These results suggest: (1) an implication of striatofrontal loops in human motivation and explicit and implicit sensitivity to reinforcement; (2) a positive influence of L-Dopa treatment on the subjective evaluation of motivation, but contrasting effects on reward sensitivity.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-3932</s0>
</fA01>
<fA02 i1="01"><s0>NUPSA6</s0>
</fA02>
<fA03 i2="1"><s0>Neuropsychologia</s0>
</fA03>
<fA05><s2>40</s2>
</fA05>
<fA06><s2>13</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Motivation, reward, and Parkinson's disease: influence of dopatherapy</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CZERNECKI (V.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>PILLON (B.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HOUETO (J. L.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>POCHON (J. B.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LEVY (R.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>DUBOIS (B.)</s1>
</fA11>
<fA14 i1="01"><s1>INSERM E 007, Hôpital de la Salpêytière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Fédération de Neurologie, Hôpital de la Salpêtrière, 47 Blvd de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>2257-2267</s1>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>11143</s2>
<s5>354000106712130060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>49 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0004494</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neuropsychologia</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>"Orbitofrontal" and "cingulate" striatofrontal loops and the mesolimbic dopaminergic system that modulates their function have been implicated in motivation and sensitivity to reinforcement in animals. Parkinson's disease (PD) provides a model to assess their implications in humans. The aims of the study were to investigate motivation and sensitivity to reinforcement in non-demented and -depressed PD patients and to evaluate the influence of dopaminergic therapy by comparing patients in "on" (with L-Dopa) and "off" (without L-Dopa) states. Twenty-three PD patients were compared, in both the "on" and "off" states, to 28 controls, using: (1) an Apathy Scale; (2) Stimulus-Reward Learning, Reversal, and Extinction tasks; and (3) a Gambling task. PD patients were found: (1) mildly apathetic; (2) impaired on Stimulus-Reward Learning and Reversal, but not on Extinction; and (3) able to progress in the Gambling task during the first, but not the second assessment. There was no significant correlation between these various deficits. L-Dopa treatment clearly improved motivation, but had more limited and contrasting effects on other variables, decreasing the number of omission errors in Reversal, but increasing the number of perseveration errors in Extinction. These results suggest: (1) an implication of striatofrontal loops in human motivation and explicit and implicit sensitivity to reinforcement; (2) a positive influence of L-Dopa treatment on the subjective evaluation of motivation, but contrasting effects on reward sensitivity.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Motivation</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Motivation</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Motivación</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Récompense</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Reward</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Recompensa</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Renforcement</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Reinforcement</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Reforzamiento</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>17</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>42</s5>
</fC07>
<fN21><s1>001</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 03-0004494 INIST</NO>
<ET>Motivation, reward, and Parkinson's disease: influence of dopatherapy</ET>
<AU>CZERNECKI (V.); PILLON (B.); HOUETO (J. L.); POCHON (J. B.); LEVY (R.); DUBOIS (B.)</AU>
<AF>INSERM E 007, Hôpital de la Salpêytière/Paris/France (1 aut., 2 aut., 4 aut., 5 aut., 6 aut.); Fédération de Neurologie, Hôpital de la Salpêtrière, 47 Blvd de l'Hôpital/75651 Paris/France (2 aut., 3 aut., 5 aut., 6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Neuropsychologia; ISSN 0028-3932; Coden NUPSA6; Royaume-Uni; Da. 2002; Vol. 40; No. 13; Pp. 2257-2267; Bibl. 49 ref.</SO>
<LA>Anglais</LA>
<EA>"Orbitofrontal" and "cingulate" striatofrontal loops and the mesolimbic dopaminergic system that modulates their function have been implicated in motivation and sensitivity to reinforcement in animals. Parkinson's disease (PD) provides a model to assess their implications in humans. The aims of the study were to investigate motivation and sensitivity to reinforcement in non-demented and -depressed PD patients and to evaluate the influence of dopaminergic therapy by comparing patients in "on" (with L-Dopa) and "off" (without L-Dopa) states. Twenty-three PD patients were compared, in both the "on" and "off" states, to 28 controls, using: (1) an Apathy Scale; (2) Stimulus-Reward Learning, Reversal, and Extinction tasks; and (3) a Gambling task. PD patients were found: (1) mildly apathetic; (2) impaired on Stimulus-Reward Learning and Reversal, but not on Extinction; and (3) able to progress in the Gambling task during the first, but not the second assessment. There was no significant correlation between these various deficits. L-Dopa treatment clearly improved motivation, but had more limited and contrasting effects on other variables, decreasing the number of omission errors in Reversal, but increasing the number of perseveration errors in Extinction. These results suggest: (1) an implication of striatofrontal loops in human motivation and explicit and implicit sensitivity to reinforcement; (2) a positive influence of L-Dopa treatment on the subjective evaluation of motivation, but contrasting effects on reward sensitivity.</EA>
<CC>002B02B06</CC>
<FD>Parkinson maladie; Motivation; Récompense; Renforcement; Chimiothérapie; Lévodopa; Dopamine; Traitement; Homme</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Antiparkinsonien</FG>
<ED>Parkinson disease; Motivation; Reward; Reinforcement; Chemotherapy; Levodopa; Dopamine; Treatment; Human</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Antiparkinson agent</EG>
<SD>Parkinson enfermedad; Motivación; Recompensa; Reforzamiento; Quimioterapia; Levodopa; Dopamina; Tratamiento; Hombre</SD>
<LO>INIST-11143.354000106712130060</LO>
<ID>03-0004494</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001034 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001034 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:03-0004494
   |texte=   Motivation, reward, and Parkinson's disease: influence of dopatherapy
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Motivation, reward, and Parkinson's disease: influence of dopatherapy

Motivation, reward, and Parkinson's disease: influence of dopatherapy

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri